Launched during RANZCO’s virtual congress, Quantel Medical’s C.Stim offers new intense pulsed light (IPL) technology for the treatment of the root causes of dry eye: meibomian gland dysfunction, inflammation and Demodex.
Premiering in Sydney and concurrent with the popular light festival, Vivid Sydney, the 2022 O-Show from 27-28 May is aspiring to be bigger and better than ever before.
The US Food and Drug Administration (FDA) has approved the first generic of Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use eye drops to increase tear production in dry eye patients.
Alcon has once again expanded its range of preservative-free eye drops with the addition of Systane COMPLETE PRESERVATIVE-FREE Lubricant Eye Drops. This lubricating eye drop combines the long-lasting formulation of Systane COMPLETE with a multi-dose, preservative-free bottle.
RNFL thickness: Alzheimer’s biomarker?
As the stresses of the global pandemic continue to take their toll on the medical profession, a new report has found that ophthalmologists appear to be coping better than their non-ophthalmological colleagues but are still struggling under the pressure.
Luxturna is now funded for patients in Australia with confirmed biallelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and, frequently, complete blindness. The move follows a
EyePoint Pharmaceuticals announced its phase 1 clinical trial of EYP-1901 for wet age-related macular degeneration (wet AMD) showed 41% of eyes required no supplemental anti-vascular endothelial
Ocular effects including chronic bilateral dacryoadenitis and Purtscher-like retinopathy have been noted in around 11% of Covid-19-positive patients, according to recent data. Dr Marco Pastore, from
A promising new retinal prosthesis using ultrasound to activate neurons could restore vision in patients with retinal degenerative diseases. “This is a step towards a retinal prosthesis that works
Macular Degeneration New Zealand (MDNZ) is hosting live educational seminars online to overwhelming positive feedback from both patients and health professionals.
Non-melanoma skin cancers (NMSCs) are the commonest cancers in Australia and New Zealand. In 2006, the age-standardised incidence of NMSCs was 406 per 100,000 population in New Zealand1. Treatment of NMSCs represents a significant cost to Australasian healthcare systems1,2 and their incidence is ris